Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 26;16(6):791. doi: 10.3390/ph16060791

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 by the author.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The ability of topical ocularly-instilled omidenepag isopropyl ester (OMDI; various concentrations; once daily), the non-prostanoid EP2-receptor agonist, to lower IOP in ocular normotensive rabbits (A), dogs (B), Cynomolgus monkey eyes (C), and in ocular hypertensive Cynomolgus monkeys (D) compared with latanoprost (xalatan; 0.005%) and/or timolol (0.05%) is shown. Note that xalatan did not lower IOP to any appreciable extent in ocular normotensive animals, unlike OMDI. In the ocular normotensive (C) and hypertensive monkeys, OMDI (0.001–0.03%) demonstrated either equivalent or greater effectiveness in lowering IOP than latanoprost (xalatan 0.005%). A second dose of OMDI lowered IOP further after the first dose (C) without inducing tachyphylaxis of the IOP-reducing effects of OMDI. The statistical significance changes verses controls (baselines) are represented by the asterisks and crosses (p < 0.05–0.0001). The arrows signify the t.o. dosing of the compound.